Eleven innovative companies with high social impact will be able to participate in a new business growth program and will have access to a laboratory at the Barcelona Science Park (PCB) for three years. This opportunity will be possible within the framework of the new BCN Health Booster accelerator , a project promoted by the PCB of the University of Barcelona and the Barcelona City Council, with the collaboration of Barcelona Activa and the support of Biocat.
Five of the selected companies are spin-offs of research centres of excellence: Aptadel Therapeutics, from the Bellvitge Institute for Biomedical Research (IDIBELL); Aptadel Therapeutics and Nuage Therapeutics, from the Institute for Research in Biomedicine (IRB Barcelona) of the UB; OneChain Immunotherapeutics, from the Josep Carreras Leukemia Research Institute, and MiMARK Diagnostics, from the Vall d’Hebron Research Institute (VHIR). The others are six start-ups: Artificial Nature, Bioliquid Innovative Genetics, Deepull Diagnostics, GAT Biosciences, GAT Therapeutics and Oncoheroes Biosciences, with innovative business projects in the health field.
At the presentation of BCN Health Booster, the rector of the UB, Joan Guārdia, highlighted that this accelerator "is a new piece of the necessary link between research, transfer and social impact, essential for the development of the city and the country as knowledge societies". "After the pandemic, it is urgent to take on the challenge of providing society with the important advances we can offer regarding health with this initiative", concluded the rector.